Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Thrombosis and Haemostasis

• Publication date

  1995-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0038-1649954PMID 8772209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WHY DO SO MANY HAEMOPHILIA A PATIENTS DEVELOP AN INHIBITOR?

  1995cited by this paper
• Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs

  1995cited by this paper
• Molecular etiology of factor VIII deficiency in hemophilia A

  1995cited by this paper
• Inhibitors in hemophilia patients: Current status and management

  1994cited by this paper
• Intron 22 inversions and haemophilia.

  1994cited by this paper
• Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition.

  1994cited by this paper
• Intron 22 inversions and haemophilia.

  1994cited by this paper
• Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.

  1994cited by this paper
• Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single‐stranded conformation polymorphism

  1994cited by this paper
• Risk of gastrointestinal bleeding from dexamethasone in children with bacterial meningitis.

  1994cited by this paper
• Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition.

  1994cited by this paper
• A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.

  1994cited by this paper
• Factor VIII gene rearrangements in patients with severe haemophilia A.

  1994cited by this paper
• Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A

  1993cited by this paper
• The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease.

  1993cited by this paper
• Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

  1993cited by this paper
• Incidence of inhibitors in haemophiliacs. A review of the literature.

  1993cited by this paper
• The molecular basis of α1-antichymotrypsin deficiency in a heterozygote with liver and lung disease

  1993cited by this paper
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

  1992cited by this paper
• Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene.

  1991cited by this paper
• Haemophilia B: database of point mutations and short additions and deletions.

  1990cited by this paper
• The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene

  1990cited by this paper
• Relationship of Major Histocompatibility Complex Class II Genes to Inhibitor Antibody Formation in Hemophilia A

  1990cited by this paper
• Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes.

  1989cited by this paper
• Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations.

  1988cited by this paper
• The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.

  1988cited by this paper
• Detection and localization of single base changes by denaturing gradient gel electrophoresis.

  1987cited by this paper
• Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis.

  1987cited by this paper
• HLA-DR and Factor VIII Antibodies in Hemophilia A

  1984cited by this paper
• Gene deletions in patients with haemophilia B and anti-factor IX antibodies

  1983cited by this paper
• HLA Antigens and Factor VIII Antibody in Classic Hemophilia

  1981cited by this paper
• The factor VIII complex: structure and function.

  1981cited by this paper
• Massive factor‐VIII infusion in Hæmophiliac with factor‐VIII inhibitor, high responder

  1977cited by this paper
• Possible Linkage between the Major Histocompatibility Complex and the Immune Response to Factor VIII in Classic Haemophilia

  1977cited by this paper
• A More Uniform Measurement of Factor VIII Inhibitors

  1975cited by this paper

• Implementation and clinical utility of multigene panels for bleeding, platelet, and thrombotic disorders.

  2025cites this paper
• Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B

  2025cites this paper
• Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience

  2024influential citation
• The Evolution of Hemophilia Therapeutics: An Illustrated Review

  2024cites this paper
• Incidence and treatment-related risk factors of inhibitor development after intensive FVIII replacement for major orthopaedic surgery in previous treated haemophilia A

  2024cites this paper
• Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study.

  2024cites this paper
• Mutational Profile in Romanian Patients with Hemophilia A

  2024cites this paper
• Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children

  2023cites this paper
• Frequency of Intron 22 Inversion in Severe Hemophilia A Patients

  2022cites this paper
• Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients

  2022cites this paper
• BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial

  2022cites this paper
• Can T-cell and B-cell excision circles predict development of inhibitors in pediatric hemophilia A?

  2022cites this paper
• Race, ethnicity, F8 variants, and inhibitor risk: analysis of the "My Life Our Future" hemophilia A database.

  2022cites this paper
• B cell–activating factor modulates the factor VIII immune response in hemophilia A

  2021cites this paper
• A Novel Molecular Indicator for Inhibitor Development in Haemophilia A

  2021influential citation
• Genetic Risk Factors for Inhibitor Development in Hemophilia A

  2021cites this paper
• Identification and functional characterization of a novel splicing variant in the F8 coagulation gene causing severe hemophilia A

  2020cites this paper
• Mutation detection and inhibitor risk in Iranian patients with Hemophilia A: Six novel mutations

  2020cites this paper
• FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A

  2020cites this paper
• Clinical Care of a Child with Hemophilia A and Inhibitors

  2020cites this paper
• Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?

  2020cites this paper
• Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study

  2020cites this paper
• FVIII inhibitor risk correlated with F8 gene variants in 296 unrelated male Chinese patients with haemophilia A

  2020cites this paper
• The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.

  2020cites this paper
• Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine

  2020cites this paper
• Molecular Mechanisms of Inhibitor Development in Hemophilia

  2020cites this paper
• Safety of recombinant coagulation factors in treating hemophilia

  2019cites this paper
• Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A.

  2019cites this paper
• Assessment of Risk Factors, which Affect the Presence of Inhibitors in Children with Hemophilia A: The Albanian Case-control Study

  2019cites this paper
• Re-personalization and stratification of hemophilia care in an evolving treatment landscape

  2019cites this paper
• An update on the ‘danger theory’ in inhibitor development in hemophilia A

  2019cites this paper
• Genetic and Molecular Testing in Thrombosis and Hemostasis: Informing Surveillance, Treatment, and Prognosis

  2019cites this paper
• Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

  2018cites this paper
• Risk factors for inhibitor development in severe hemophilia a.

  2018cites this paper
• In silico and in vitro immunogenicity assessment of B‐domain‐modified recombinant factor VIII molecules

  2018cites this paper
• Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A

  2018cites this paper
• A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third‐generation B‐domain‐deleted recombinant factor VIII

  2018cites this paper
• Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate®: Final report from a prospective study

  2018cites this paper
• Prevention and Management of Bleeding Episodes in Children with Hemophilia

  2018cites this paper
• Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy

  2018cites this paper
• Management of Hemophilia Patient

  2017cites this paper
• Neue Entwicklungen in der molekularbiologischen Diagnostik

  2017cites this paper
• Stratégies thérapeutiques contre la réponse immunitaire anti-Facteur VIII chez l'hémophile A : par modification de la structure du FVIII, par inhibition de la signalisation des lymphocytes B

  2017cites this paper
• Molecular Diagnostics for Coagulopathies

  2017cites this paper
• Hemophilia A and B : An Overview

  2017cites this paper
• Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.

  2017cites this paper
• In silico Analysis of Single Nucleotide Polymorphisms (SNPS) in Human Factor VIII Gene

  2017cites this paper
• 5 Hemophilia Inhibitors Prevalence , Causes and Diagnosis

  2017cites this paper
• [New developments in molecularbiological diagnostic].

  2017cites this paper
• Progress in the contemporary management of hemophilia: The new issue of patient aging.

  2017cites this paper
• Anti-factorVIII antibodies A 2005 update

  2017cites this paper
• Prevalence of Inhibitors to Factor VIII after 25 Exposures to Factor VIII Concentrates and/or Blood Products in Persons with Hemophilia A

  2017cites this paper
• Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

  2016cites this paper
• Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A

  2016cites this paper
• A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor

  2016influential citation
• Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A

  2016cites this paper
• A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

  2016cites this paper
• Short title: Promiscuity of factor VIII

  2016cites this paper
• T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.

  2016cites this paper
• Achievements, challenges and unmet needs for haemophilia patients with inhibitors

  2016cites this paper
• Prevalence of IVS10nt-18G/A in Calabrian patients with moderate/mild hemophilia A and relation with Factor VIII inhibitor antibodies

  2015cites this paper
• Prevalence of Inhibitors in Patients with Hemophilia Treated with Factor VIII or IX Transfusion in Coimbatore Medical College Hospital

  2015cites this paper
• Risk factors associated with inhibitor development in Chinese patients with haemophilia B

  2015cites this paper
• Actualité sur le risque de survenue d’inhibiteur à l’initiation du traitement par concentré de facteur VIII dans l’hémophilie A sévère

  2015cites this paper
• A large‐scale computational study of inhibitor risk in non‐severe haemophilia A

  2015cites this paper
• Wykrywanie mutacji inwersyjnych (INV22 oraz INV1) w genie F8 metodą IS-PCR u polskich chorych na ciężką hemofilię A

  2015cites this paper
• Practice Guidelines for the Molecular Diagnosis of Haemophilia A

  2015cites this paper
• Historical Review on Genetic Analysis in Hemophilia A

  2014cites this paper
• Genomics of bleeding disorders

  2014cites this paper
• Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors

  2014cites this paper
• Badania genetyczne w diagnostyce hemofilii A Genetic testing in hemophilia A diagnostics

  2014cites this paper
• Factor VIII therapy for hemophilia A: current and future issues

  2014cites this paper
• Erworbene Hemmkörperhämophilie

  2014cites this paper
• Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry

  2014cites this paper
• In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene

  2014cites this paper
• Plasma Components as Targets of Damage

  2014cites this paper
• Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

  2013cites this paper
• The Canadian “National Program for hemophilia mutation testing” database: A ten‐year review

  2013cites this paper
• Molecular determinants of FVIII immunogenicity in hemophilia A

  2013cites this paper
• Management of dental extraction in patients with Haemophilia A and B: A report of 58 extractions

  2013cites this paper
• hemophilia A: the CANAL cohort study development of inhibitors in previously untreated patients with severe Recombinant versus plasma-derived factor VIII products and the

  2013cites this paper
• untreated patients with hemophilia A: the CANAL cohort study Treatment-related risk factors of inhibitor development in previously

  2013cites this paper
• Hyperimmune globulins and same‐day thrombotic adverse events as recorded in a large healthcare database during 2008–2011

  2013cites this paper
• Identifying Nongenetic Risk Factors for Inhibitor Development in Severe Hemophilia A

  2013cites this paper
• Factor VIII products and inhibitor development in severe hemophilia A.

  2013cites this paper
• inhibitors in previously untreated patients with severe hemophilia A Influence of the type of factor VIII concentrate on the incidence of factor VIII

  2013cites this paper
• cofactor activity and binding to von Willebrand factor A human antibody directed to the factor VIII C1 domain inhibits factor VIII

  2013cites this paper
• The Canadian “National Program for hemophilia mutation testing” database: A ten‐year review

  2013cites this paper
• Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management

  2013cites this paper
• identification of an inhibitory antibody epitope on the surface of factor VIII Fab complex: κ immunoglobulin G4 - Structure of a factor VIII C2 domain

  2013cites this paper
• High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance

  2013cites this paper
• UvA-DARE ( Digital Academic Repository ) Molecular determinants of FVIII immunogenicity in hemophilia

  2013cites this paper
• Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update

  2013cites this paper
• Profiling of differentially expressed genes in haemophilia A with inhibitor

  2012cites this paper
• F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.

  2012cites this paper
• Genetics of haemostasis

  2012cites this paper
• Requirements for immune recognition and processing of factor VIII by antigen-presenting cells.

  2012cites this paper
• Caracterização das alterações genéticas em hemofílicos A graves do Rio Grande do Sul

  2012cites this paper
• Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A

  2012cites this paper
• F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

  2012cites this paper